Papers in EJC Skin Cancer
Page 1 · newest first
- Modality-Specific Prognostic and Predictive Factors in Metastatic Uveal MelanomaEJC Skin Cancer · 2026
- Ten-year outcomes after initial response to immune checkpoint inhibitors in patients with advanced Merkel cell carcinomaEJC Skin Cancer · 2026
- Predictors of clinical and pathological response in patients with basal cell carcinoma treated with BO-112, a novel intralesional treatmentEJC Skin Cancer · 2026
- Non-treatment as a valuable treatment option in older adults with basal cell carcinoma?EJC Skin Cancer · 2026
- PI3K Inhibition and PD-1 Blockade in Advanced Anal Canal CarcinomaEJC Skin Cancer · 2026
- Clinical and Patient-Reported Outcomes in C-POST: Phase 3 Trial of Adjuvant Cemiplimab versus Placebo for High-Risk Cutaneous Squamous Cell CarcinomaEJC Skin Cancer · 2026
- Bone metastases in melanoma: a real-world clinical and radiological descriptive analysisEJC Skin Cancer · 2026
- Extraskeletal Ewing Sarcoma of the Nail Unit Mimicking Subungual Melanoma: A Rare Acral EntityEJC Skin Cancer · 2026
- Real-world outcomes of palliative anti–programmed cell death protein 1 monotherapy in patients aged ≥75 years with advanced melanomaEJC Skin Cancer · 2026
- Radiotherapy Outcomes in Distal Limb Skin Cancers Treated at a Large District General HospitalEJC Skin Cancer · 2026
- Sarcoid-like reaction associated with immune checkpoint inhibitor: To be, or not to be, that is the question.EJC Skin Cancer · 2026
- Proteomic profiling identifies response-associated pathways in immunotherapy-treated melanomaEJC Skin Cancer · 2026
- De-escalation of targeted therapy in melanoma: A literature reviewEJC Skin Cancer · 2026
- Duration of sonidegib treatment and its relationship with recurrence after complete response: a multicenter retrospective studyEJC Skin Cancer · 2026
- Episode-Based Melanoma Risk Stratification Using Artificial Intelligence:Development and Validation of Time-Updated Prognostic ModelsEJC Skin Cancer · 2026
- Landmark overall survival of 89% at one year among patients with anti-PD1 refractory metastatic melanoma treated with evalstotug, a conditionally binding anti-CTLA-4 antibodyEJC Skin Cancer · 2026
- Successful Cemiplimab Therapy in a Very Elderly Patient with Cutaneous Squamous Cell Carcinoma: A Case ReportEJC Skin Cancer · 2026
- Therapeutic challenges in oral mucosal melanoma: two clinical casesEJC Skin Cancer · 2026
- Mortality trends of melanoma in Germany from 2001 to 2020EJC Skin Cancer · 2026
- Efficacy and safety of RP1 plus nivolumab in patients with non-melanoma skin cancerEJC Skin Cancer · 2026
- Multimodal vascular imaging of cutaneous neoplasms using dermoscopy, dynamic optical coherence tomography and line-field confocal optical coherence tomographyEJC Skin Cancer · 2026
- Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic MelanomaEJC Skin Cancer · 2026
- A Phase II Single Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy with Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)EJC Skin Cancer · 2026
- Genetic alterations and prognosis in extramammary Paget disease: potential roles of somatic CDKN2A variants in poor outcomesEJC Skin Cancer · 2026
- Beyond Clinical Exams: when AI-assisted multimodal imaging detects featureless dermoscopic basal cell carcinomaEJC Skin Cancer · 2026
- Malignant variant of a well-known entityEJC Skin Cancer · 2026
- Results of the Euromelanoma 2025 campaign in Spain.EJC Skin Cancer · 2026
- Onset of Poliosis is linked to Durable Response to Immune-Checkpoint Blockade in Metastatic Melanoma Patients: A Multicenter Case SeriesEJC Skin Cancer · 2026
- Immune-related pneumonitis: A retrospective analysis of corticosteroid requirements and the role of hydroxychloroquine in melanoma patientsEJC Skin Cancer · 2026
- 10-years of first-line ipilimumab and nivolumab in the management of melanoma brain metastases: a single centre experienceEJC Skin Cancer · 2026
- Immune-related GFAP-Astrocytopathy under PD-1 Inhibition: A Case ReportEJC Skin Cancer · 2026
- PD-L1 Assessment in Merkel Cell Carcinoma: Predictive Implications for Anti-PD-1 and Anti-PD-L1 TherapyEJC Skin Cancer · 2026
- Rapid reduction of immune checkpoint inhibitor–associated pruritus with nemolizumabEJC Skin Cancer · 2026
- Validation of a Prognostic microRNA Signature in Early-Stage Melanoma Across NanoString and RNA-Sequencing PlatformsEJC Skin Cancer · 2026
- Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025EJC Skin Cancer · 2026
- Comparative analysis of progression free survival and treatment maintenance in patients with advanced melanoma responding to first-line treatmentEJC Skin Cancer · 2026
- Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatmentEJC Skin Cancer · 2026
- Living with advanced or metastatic melanoma: A patient-driven conceptual modelEJC Skin Cancer · 2026
- Complete response with combined sonidegib and pembrolizumab in synchronous advanced basal cell carcinoma and metastatic cutaneous squamous cell carcinoma: A case reportEJC Skin Cancer · 2026
- Rethinking locoregional therapy of Merkel cell carcinoma in the era of immune checkpoint inhibitionEJC Skin Cancer · 2026
- Cutaneous Adenocarcinomas: Patterns of Presentation, Management, and Prognosis in a Five-Year Single-Center ExperienceEJC Skin Cancer · 2026
- Dermatofibrosarcoma protuberans in South Africa: Outcomes of staged excision and peripheral and deep en face margin assessment (PDEMA) and recommendations for wide local excision marginsEJC Skin Cancer · 2026
- Registry-based survival analysis of high-risk melanoma patients in Serbia: the impact of adjuvant treatment for stage III diseaseEJC Skin Cancer · 2026
- The recurrence rate of malignant melanoma treated with staged micrographic excision in South Africa: A retrospective studyEJC Skin Cancer · 2026
- Long-term outcomes of cutaneous basal cell and squamous cell carcinomas with < 1 mm close primary surgical excision margins managed in a UK tertiary centre multidisciplinary teamEJC Skin Cancer · 2026
- Neutropenia induced by dabrafenib and trametinib combination therapy in patients with melanoma: Incidence, risk factors and clinical implicationsEJC Skin Cancer · 2026
- From immune activation to pathological response: neoadjuvant immunotherapy in cutaneous squamous cell carcinoma. A systematic review and meta-analysisEJC Skin Cancer · 2026
- Exceptional case of tumor lysis syndrome following Encorafénib-Binimétinib therapy for metastatic melanomaEJC Skin Cancer · 2026
- Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced cutaneous squamous cell carcinomaEJC Skin Cancer · 2026
- BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter studyEJC Skin Cancer · 2026